174 related articles for article (PubMed ID: 28882915)
21. Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT.
Michielsen K; Vergote I; Op de Beeck K; Amant F; Leunen K; Moerman P; Deroose C; Souverijns G; Dymarkowski S; De Keyzer F; Vandecaveye V
Eur Radiol; 2014 Apr; 24(4):889-901. PubMed ID: 24322510
[TBL] [Abstract][Full Text] [Related]
22. Assessment of whole-body MRI including diffusion-weighted sequences in the initial staging of breast cancer patients at high risk of metastases in comparison with PET-CT: a prospective cohort study.
Hottat NA; Badr DA; Ben Ghanem M; Besse-Hammer T; Lecomte SM; Vansteelandt C; Lecomte SL; Khaled C; De Grove V; Salem Wehbe G; Cannie MM; Jani JC
Eur Radiol; 2024 Jan; 34(1):165-178. PubMed ID: 37555959
[TBL] [Abstract][Full Text] [Related]
23. Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging.
Johnston EW; Latifoltojar A; Sidhu HS; Ramachandran N; Sokolska M; Bainbridge A; Moore C; Ahmed HU; Punwani S
Eur Radiol; 2019 Jun; 29(6):3159-3169. PubMed ID: 30519933
[TBL] [Abstract][Full Text] [Related]
24. Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT.
Schmidt GP; Schoenberg SO; Schmid R; Stahl R; Tiling R; Becker CR; Reiser MF; Baur-Melnyk A
Eur Radiol; 2007 Apr; 17(4):939-49. PubMed ID: 16951929
[TBL] [Abstract][Full Text] [Related]
25. Whole-body MRI for staging and interim response monitoring in paediatric and adolescent Hodgkin's lymphoma: a comparison with multi-modality reference standard including
Latifoltojar A; Punwani S; Lopes A; Humphries PD; Klusmann M; Menezes LJ; Daw S; Shankar A; Neriman D; Fitzke H; Clifton-Hadley L; Smith P; Taylor SA
Eur Radiol; 2019 Jan; 29(1):202-212. PubMed ID: 29948084
[TBL] [Abstract][Full Text] [Related]
26. [Importance of whole body MRI for staging of colorectal cancer].
Schmidt G
Radiologe; 2012 Jun; 52(6):537-44. PubMed ID: 22618626
[TBL] [Abstract][Full Text] [Related]
27. Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer.
Schmidt GP; Baur-Melnyk A; Haug A; Utzschneider S; Becker CR; Tiling R; Reiser MF; Hermann KA
Eur Radiol; 2009 Jun; 19(6):1366-78. PubMed ID: 19190917
[TBL] [Abstract][Full Text] [Related]
28. Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.
Sommer G; Wiese M; Winter L; Lenz C; Klarhöfer M; Forrer F; Lardinois D; Bremerich J
Eur Radiol; 2012 Dec; 22(12):2859-67. PubMed ID: 22772365
[TBL] [Abstract][Full Text] [Related]
29. Preoperative staging of ovarian cancer: comparison between ultrasound, CT and whole-body diffusion-weighted MRI (ISAAC study).
Fischerova D; Pinto P; Burgetova A; Masek M; Slama J; Kocian R; Frühauf F; Zikan M; Dusek L; Dundr P; Cibula D
Ultrasound Obstet Gynecol; 2022 Feb; 59(2):248-262. PubMed ID: 33871110
[TBL] [Abstract][Full Text] [Related]
30. Whole-body MRI: a powerful alternative to bone scan for bone marrow staging without radiation and gadolinium enhancer.
Papageorgiou I; Dvorak J; Cosma I; Pfeil A; Teichgraeber U; Malich A
Clin Transl Oncol; 2020 Aug; 22(8):1321-1328. PubMed ID: 31858434
[TBL] [Abstract][Full Text] [Related]
31. Whole-body diffusion-weighted MRI for operability assessment in patients with colorectal cancer and peritoneal metastases.
Dresen RC; De Vuysere S; De Keyzer F; Van Cutsem E; Prenen H; Vanslembrouck R; De Hertogh G; Wolthuis A; D'Hoore A; Vandecaveye V
Cancer Imaging; 2019 Jan; 19(1):1. PubMed ID: 30616608
[TBL] [Abstract][Full Text] [Related]
32. Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation.
Leaviss J; Davis S; Ren S; Hamilton J; Scope A; Booth A; Sutton A; Parry G; Buszewicz M; Moss-Morris R; White P
Health Technol Assess; 2020 Sep; 24(46):1-490. PubMed ID: 32975190
[TBL] [Abstract][Full Text] [Related]
33. Detection of distant metastases in rectal cancer: contrast-enhanced CT vs whole body MRI.
Yoon JH; Yu MH; Hur BY; Park CM; Lee JM
Eur Radiol; 2021 Jan; 31(1):104-111. PubMed ID: 32789755
[TBL] [Abstract][Full Text] [Related]
34. Predictors of distress among patients undergoing staging investigations for suspected colorectal and lung cancer.
Miles A; Evans REC; Taylor SA
Psychol Health Med; 2021 Aug; 26(7):887-898. PubMed ID: 33232621
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic bone imaging in patients with prostate cancer: patient experience and acceptance of NaF-PET/CT, choline-PET/CT, whole-body MRI, and bone SPECT/CT.
Dyrberg E; Larsen EL; Hendel HW; Thomsen HS
Acta Radiol; 2018 Sep; 59(9):1119-1125. PubMed ID: 29313360
[TBL] [Abstract][Full Text] [Related]
36. Whole-body MRI vs bone scintigraphy in the staging of Ewing sarcoma of bone: a 12-year single-institution review.
Kalus S; Saifuddin A
Eur Radiol; 2019 Oct; 29(10):5700-5708. PubMed ID: 30915559
[TBL] [Abstract][Full Text] [Related]
37. Patient centered radiology: investigating 3 Tesla whole body MRI acceptance in cancer patients.
Rossi A; Prochowski Iamurri A; Diano D; Oboldi D; Sintuzzi E; Maurizio L; Andalò A; Cavallucci M; Ferroni F; Amadori E; Barone D; Petralia G
Radiol Med; 2023 Aug; 128(8):960-969. PubMed ID: 37395842
[TBL] [Abstract][Full Text] [Related]
38. Colorectal cancer staging: comparison of whole-body PET/CT and PET/MR.
Catalano OA; Coutinho AM; Sahani DV; Vangel MG; Gee MS; Hahn PF; Witzel T; Soricelli A; Salvatore M; Catana C; Mahmood U; Rosen BR; Gervais D
Abdom Radiol (NY); 2017 Apr; 42(4):1141-1151. PubMed ID: 27891551
[TBL] [Abstract][Full Text] [Related]
39. Comparison of contrast-enhanced CT, dual-layer detector spectral CT, and whole-body MRI in suspected metastatic breast cancer: a prospective diagnostic accuracy study.
Buus TW; Rasmussen F; Nellemann HM; Løgager V; Jensen AB; Hauerslev KR; Christiansen P; Pedersen EM
Eur Radiol; 2021 Dec; 31(12):8838-8849. PubMed ID: 34008104
[TBL] [Abstract][Full Text] [Related]
40. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
Aquino SL; Fischman AJ
Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
